Welcome to our dedicated page for Adc Therapeutics Sa SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADC Therapeutics SA (NYSE: ADCT) SEC filings page brings together the company’s U.S. regulatory disclosures, offering investors structured access to its official communications. ADC Therapeutics is a commercial-stage oncology company focused on antibody drug conjugates, led by its CD19-directed therapy ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
In its recent Form 8-K filings, the company has reported preliminary revenue and cash estimates, updated clinical data from the LOTIS-7 Phase 1b trial of ZYNLONTA combinations, and the availability of corporate presentations. Other 8-Ks describe private placement agreements, unregistered sales of equity securities, and quarterly financial result announcements via attached press releases. These filings also confirm that ADC Therapeutics’ common shares trade on the New York Stock Exchange under the symbol ADCT.
Through this page, users can review filings that explain how ZYNLONTA’s accelerated and conditional approvals are being supported by confirmatory trials such as LOTIS-5 and LOTIS-7, as well as documents detailing capital-raising activities and other material events. Forms related to results of operations, material agreements, and investor presentations help clarify the company’s financial condition, clinical strategy, and risk disclosures.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points from lengthy filings, such as major clinical milestones, revenue commentary, or financing terms. Real-time updates from EDGAR, combined with simplified views of 8-Ks and other reports, allow investors researching ADCT to quickly understand what each filing means without reading every line. This makes it easier to follow ADC Therapeutics’ regulatory history, clinical progress, and corporate transactions over time.
ADC Therapeutics SA filed a Form S-8 on August 12, 2025 to register 4,850,000 additional common shares (par value CHF 0.08) for issuance under the ADC Therapeutics SA 2019 Equity Incentive Plan. The filing incorporates by reference prior Form S-8 registrations filed on March 15, 2023 and June 30, 2022 and references periodic reports filed in 2025.
Exhibits listed include amended and restated articles, a Swiss counsel opinion, the consent of PricewaterhouseCoopers SA, the amended plan and a filing fee table.
ADC Therapeutics reported consolidated revenue of $18.8 million for the quarter and $41.9 million for the six months, driven by U.S. product sales of ZYNLONTA and increased license/royalty income. The company recorded a net loss of $56.6 million for the quarter and $95.2 million for the six months, reflecting higher R&D spending and a $13.1 million charge for restructuring and impairments tied to a plan to close the UK facility and reduce global headcount by approximately 30%.
Liquidity was strengthened by a June private placement that generated gross $100.0 million (net $93.1 million), leaving cash and cash equivalents at $264.6 million. Material longer-term obligations include a deferred royalty obligation (fair value ~$312.0 million, carrying balance rolled to $340.4 million in the rollforward) and senior secured term loans with a carrying value of $114.5 million and an effective interest rate of 16.15%. Shareholders' deficit was $(199.2) million at June 30, 2025.
ADC Therapeutics SA reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company filed a Current Report on Form 8-K to attach that press release as Exhibit 99.1, and the filing also includes a Cover Page Interactive Data File as Exhibit 104.
The filing states that the information in Item 2.02 and Exhibit 99.1 is incorporated by reference but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The report is signed on behalf of the company by Jose Carmona, Chief Financial Officer. The 8-K itself does not include the detailed financial tables or results within the body of the filing.